BCOP Exam Questions with Correct Answers| Latest Update Guaranteed Success
melanoma - Stage I or II surgery
melanoma - Stage III nivolumab, ipilumumab
melanoma - BRAF positive Stage III dabrafenib + trametinib
melanoma - BRAF positive Stage IV, aggressive, bulky, symptomatic dabrafenib + trametinib,
vemurafenib + cobimetinib
melanoma - Unresectable stage III with in-transit lesions Talimogene Laherparepvec (T-VEC)
melanoma - Stage IV nivolumab, pembrolizumab
melanoma - BRAF positive Stage IV minimally symptomatic nivolumab, pembrolizumab,
nivolumab + ipilimumab (Stage IV immunotherapy)
metastatic basal cell carcinoma vismodegib, sonidegib
CLL - Age < 65 without significant comorbidies without del 17p/TP53 FCR, ibrutinib,
bendamustine with or without cd20 MoAb
CLL - Age < 65 without significant comorbidities without del 17p/TP53 relapse/refractory
ibrutinib, idelalisib + R, venetoclax with or without R
CLL - Age < 65 without significant comorbidies without del 17p/TP53 maintenance consider
lenalidomide for high risk
,CLL - Age > 65 or younger patients with significant comorbidities without del 17p/TP53
Obinutuzumab + chlorambucil, ibrutinib, ofatumumab + chlorambucil, rituxan +
chlorambucil, bendamustine with or without R
CLL - Age > 65 or younger patients with significant comorbidities without del 17p/TP53
maintenance consider lenalidomide for high risk
CLL - Age > 65 or younger patients with significant comorbidities without del 17p/TP53
relapse/refractory ibrutinib, idelalisib + R, venetoclax with or without R
CLL - Frail patients with significant comorbidities without del 17p/TP53 Obinutuzumab +
chlorambucil, ibrutinib, ofatumumab + chlorambucil, rituxan + chlorambucil
CLL - Frail patients with significant comorbidities without del 17p/TP53 maintenance
consider lenalidomide for high risk
Frail patients with significant comorbidities without del 17p/TP53 relapsed/refractory
ibrutinib, idelalisib + R, venetoclax with or without R
CLL - With del 17p/TP53 ibrutinib**, HDMP + rituxan, obinutuzumab, alemtuzumab with or
without rituxan
CLL - With del 17p/TP53 relapsed/refractory ibrutinib, idelalisib + R, venetoclax with or
without R
CLL - With del 17p/TP53 maintenance consider lenalidomide for high risk
NSCLC stage IA surgery
,NSCLC stage IB surgery
NSCLC stage IIA surgery followed by cisplatin doublet
NSCLC stage IIB surgery followed by cisplatin doublet
NSCLC stage IIIA surgery followed by cisplatin doublet
NSCLC stage IIIB surgery followed by cisplatin doublet + XRT
NSCLC stage III consolidation durvalumab
NSCLC stage IV PD-LI >50% pembrolizumab
NSCLC stage IV SCC cisplatin/gemcitabine
NSCLC stage IV adenocarcinoma no driver mutation, no PD-L1 expression platinum based
doublet or carbo/pem/pem
NSCLC stage IV nonsquamous EGFR positive erlotinib, afatinib, gefitinib, osimertinib (2a rec)
NSCLC stage IV nonsquamous T790M mutation osimertinib
NSCLC stage IV nonsquamous EML4-ALK positive alectinib (preferred), crizotinib, ceritinib
NSCLC stage IV nonsquamous ROS-1 positive crizotinib, ceritinib
, NSCLC stage IV nonsquamous BRAF V600E positive dabrafenib+trametinib
NSCLC continuation maintenance pemetrexed (nonsquamous), pemetrexed/avastin, gemzar
NSCLC switch maintenance pemetrexed (nonsquamous), docetaxel
NSCLC stage IV nonsquamous EGFR positive second line erlotinib, gefitinib, afatanib
NSCLC stage IV nonsquamous EGFR positive third line chemo preferred over
immunotherapy
NSCLC stage IV nonsquamous ALK positive second line ceritinib, alectinib, brigatinib
NSCLC stage IV nonsquamous ALK positive third line chemo preferred over immunotherapy
NSCLC stage IV second line after progression on platinum based chemo (immunotherapy)
nivolumab, pembrolizumab (PD-L1 >1%), atezolizumab
NSCLC stage IV second line after progression on platinum based chemo (chemo) docetaxel,
pemetrexed, ramucirumab+docetaxel
Stage IV mesothelioma Pemetrexed/cisplatin (category 1), pemetrexed/cisplatin/avastin
(category 2)
Stage 1A or stage 1B (grade 1 and 2) ovarian surgical staging + observation. taxane/carbo for
3-6 cycles if grade 2
melanoma - Stage I or II surgery
melanoma - Stage III nivolumab, ipilumumab
melanoma - BRAF positive Stage III dabrafenib + trametinib
melanoma - BRAF positive Stage IV, aggressive, bulky, symptomatic dabrafenib + trametinib,
vemurafenib + cobimetinib
melanoma - Unresectable stage III with in-transit lesions Talimogene Laherparepvec (T-VEC)
melanoma - Stage IV nivolumab, pembrolizumab
melanoma - BRAF positive Stage IV minimally symptomatic nivolumab, pembrolizumab,
nivolumab + ipilimumab (Stage IV immunotherapy)
metastatic basal cell carcinoma vismodegib, sonidegib
CLL - Age < 65 without significant comorbidies without del 17p/TP53 FCR, ibrutinib,
bendamustine with or without cd20 MoAb
CLL - Age < 65 without significant comorbidities without del 17p/TP53 relapse/refractory
ibrutinib, idelalisib + R, venetoclax with or without R
CLL - Age < 65 without significant comorbidies without del 17p/TP53 maintenance consider
lenalidomide for high risk
,CLL - Age > 65 or younger patients with significant comorbidities without del 17p/TP53
Obinutuzumab + chlorambucil, ibrutinib, ofatumumab + chlorambucil, rituxan +
chlorambucil, bendamustine with or without R
CLL - Age > 65 or younger patients with significant comorbidities without del 17p/TP53
maintenance consider lenalidomide for high risk
CLL - Age > 65 or younger patients with significant comorbidities without del 17p/TP53
relapse/refractory ibrutinib, idelalisib + R, venetoclax with or without R
CLL - Frail patients with significant comorbidities without del 17p/TP53 Obinutuzumab +
chlorambucil, ibrutinib, ofatumumab + chlorambucil, rituxan + chlorambucil
CLL - Frail patients with significant comorbidities without del 17p/TP53 maintenance
consider lenalidomide for high risk
Frail patients with significant comorbidities without del 17p/TP53 relapsed/refractory
ibrutinib, idelalisib + R, venetoclax with or without R
CLL - With del 17p/TP53 ibrutinib**, HDMP + rituxan, obinutuzumab, alemtuzumab with or
without rituxan
CLL - With del 17p/TP53 relapsed/refractory ibrutinib, idelalisib + R, venetoclax with or
without R
CLL - With del 17p/TP53 maintenance consider lenalidomide for high risk
NSCLC stage IA surgery
,NSCLC stage IB surgery
NSCLC stage IIA surgery followed by cisplatin doublet
NSCLC stage IIB surgery followed by cisplatin doublet
NSCLC stage IIIA surgery followed by cisplatin doublet
NSCLC stage IIIB surgery followed by cisplatin doublet + XRT
NSCLC stage III consolidation durvalumab
NSCLC stage IV PD-LI >50% pembrolizumab
NSCLC stage IV SCC cisplatin/gemcitabine
NSCLC stage IV adenocarcinoma no driver mutation, no PD-L1 expression platinum based
doublet or carbo/pem/pem
NSCLC stage IV nonsquamous EGFR positive erlotinib, afatinib, gefitinib, osimertinib (2a rec)
NSCLC stage IV nonsquamous T790M mutation osimertinib
NSCLC stage IV nonsquamous EML4-ALK positive alectinib (preferred), crizotinib, ceritinib
NSCLC stage IV nonsquamous ROS-1 positive crizotinib, ceritinib
, NSCLC stage IV nonsquamous BRAF V600E positive dabrafenib+trametinib
NSCLC continuation maintenance pemetrexed (nonsquamous), pemetrexed/avastin, gemzar
NSCLC switch maintenance pemetrexed (nonsquamous), docetaxel
NSCLC stage IV nonsquamous EGFR positive second line erlotinib, gefitinib, afatanib
NSCLC stage IV nonsquamous EGFR positive third line chemo preferred over
immunotherapy
NSCLC stage IV nonsquamous ALK positive second line ceritinib, alectinib, brigatinib
NSCLC stage IV nonsquamous ALK positive third line chemo preferred over immunotherapy
NSCLC stage IV second line after progression on platinum based chemo (immunotherapy)
nivolumab, pembrolizumab (PD-L1 >1%), atezolizumab
NSCLC stage IV second line after progression on platinum based chemo (chemo) docetaxel,
pemetrexed, ramucirumab+docetaxel
Stage IV mesothelioma Pemetrexed/cisplatin (category 1), pemetrexed/cisplatin/avastin
(category 2)
Stage 1A or stage 1B (grade 1 and 2) ovarian surgical staging + observation. taxane/carbo for
3-6 cycles if grade 2
